Crinetics Pharmaceuticals, Inc. (CRNX)
84.79
+0.10
(+0.12%)
USD |
NASDAQ |
Aug 24, 16:00
84.79
0.00 (0.00%)
After-Hours: 20:00
Crinetics Pharmaceuticals Total Liabilities (Quarterly) : 129.92M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 129.92M |
| March 31, 2026 | 120.68M |
| December 31, 2025 | 143.41M |
| September 30, 2025 | 123.86M |
| June 30, 2025 | 118.05M |
| March 31, 2025 | 107.33M |
| December 31, 2024 | 401.32M |
| September 30, 2024 | 104.39M |
| June 30, 2024 | 104.77M |
| March 31, 2024 | 103.22M |
| December 31, 2023 | 96.25M |
| September 30, 2023 | 93.79M |
| June 30, 2023 | 39.14M |
| March 31, 2023 | 33.68M |
| December 31, 2022 | 35.85M |
| September 30, 2022 | 33.51M |
| June 30, 2022 | 35.57M |
| March 31, 2022 | 30.24M |
| Date | Value |
|---|---|
| December 31, 2021 | 19.07M |
| September 30, 2021 | 15.77M |
| June 30, 2021 | 15.49M |
| March 31, 2021 | 14.07M |
| December 31, 2020 | 14.53M |
| September 30, 2020 | 13.10M |
| June 30, 2020 | 14.35M |
| March 31, 2020 | 15.45M |
| December 31, 2019 | 13.24M |
| September 30, 2019 | 12.99M |
| June 30, 2019 | 13.05M |
| March 31, 2019 | 14.37M |
| December 31, 2018 | 11.19M |
| September 30, 2018 | 9.16M |
| June 30, 2018 | 6.905M |
| March 31, 2018 | 3.33M |
| December 31, 2017 | 0.92M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 7.175B |
| Johnson & Johnson | 116.09B |
| Eli Lilly & Co. | 108.40B |
| Pfizer Inc. | 115.64B |
| Bristol Myers Squibb Co. | 65.32B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.322B |
| Shareholders Equity (Quarterly) | 1.192B |
| Debt to Equity Ratio | 0.0396 |
| Current Ratio | 15.57 |
| Net Debt Paydown Yield | 0.02% |